Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:LCI
- CUSIP: 51601210
- Web: www.lannett.com
Capitalization:- Market Cap: $776.25 million
- Outstanding Shares: 37,231,000
Average Prices:- 50 Day Moving Avg: $20.40
- 200 Day Moving Avg: $21.49
- 52 Week Range: $16.75 - $39.99
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 7.19
- P/E Growth: -0.91
Sales & Book Value:- Annual Revenue: $667.11 million
- Price / Sales: 1.16
- Book Value: $15.02 per share
- Price / Book: 1.39
Profitability:- EBIDTA: $261.24 million
- Net Margins: -0.41%
- Return on Equity: 22.13%
- Return on Assets: 6.99%
Debt:- Debt-to-Equity Ratio: 1.54%
- Current Ratio: 2.63%
- Quick Ratio: 2.04%
Misc:- Average Volume: 635,098 shs.
- Beta: 2.71
- Short Ratio: 27.97
Frequently Asked Questions for Lannett Co (NYSE:LCI)
What is Lannett Co's stock symbol?
Lannett Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LCI."
How were Lannett Co's earnings last quarter?
Lannett Co Inc (NYSE:LCI) released its quarterly earnings data on Tuesday, May, 2nd. The company reported $0.77 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.87 by $0.10. The firm had revenue of $165.72 million for the quarter, compared to the consensus estimate of $170.28 million. Lannett Co had a negative net margin of 0.41% and a positive return on equity of 22.13%. View Lannett Co's Earnings History.
When will Lannett Co make its next earnings announcement?
Where is Lannett Co's stock going? Where will Lannett Co's stock price be in 2017?
6 analysts have issued 1-year price objectives for Lannett Co's shares. Their forecasts range from $18.00 to $43.00. On average, they expect Lannett Co's share price to reach $28.00 in the next year. View Analyst Ratings for Lannett Co.
Who are some of Lannett Co's key competitors?
Some companies that are related to Lannett Co include Innoviva (INVA), Impax Laboratories (IPXL), Corcept Therapeutics Incorporated (CORT), Amphastar Pharmaceuticals (AMPH), AMAG Pharmaceuticals (AMAG), SciClone Pharmaceuticals (SCLN), Aceto Corporation (ACET), Teligent (TLGT), Collegium Pharmaceutical (COLL), Aquinox Pharmaceuticals (AQXP), Tetraphase Pharmaceuticals (TTPH), Corium International (CORI), BioDelivery Sciences International (BDSI), Allergy Therapeutics plc (AGY), Neos Therapeutics (NEOS), Adamis Pharmaceuticals Corporation (ADMP), Aralez Pharmaceuticals (ARLZ) and Intellipharmaceutics International (IPCI).
Who are Lannett Co's key executives?
Lannett Co's management team includes the folowing people:
- Jeffrey Farber, Chairman of the Board
- Arthur P. Bedrosian J.D., Chief Executive Officer, Director
- Martin P. Galvan CPA, Chief Financial Officer, Vice President - Finance, Treasurer
- Robert Ehlinger, Vice President - Logistics, Chief Information Officer
- Samuel H. Israel, Vice President, General Counsel, Chief Legal Officer
- Kevin R. Smith, Vice President - Sales and Marketing
- John M. Abt, Vice President of Quality
- Kristin A Arnold, Vice President - Research and Development
- David Drabik, Lead Independent Director
- James M. Maher, Independent Director
Who owns Lannett Co stock?
Lannett Co's stock is owned by many different of institutional and retail investors. Top institutional investors include Russell Investments Group Ltd. (1.42%), Adams Diversified Equity Fund Inc. (0.07%), First Quadrant L P CA (0.05%), Hollencrest Securities LLC (0.04%), Louisiana State Employees Retirement System (0.03%) and Public Employees Retirement Association of Colorado (0.02%). Company insiders that own Lannett Co stock include Arthur P Bedrosian, David A Drabik, David Farber, G Michael Landis, James M Maher, John Abt, Kevin Smith, Martin P Galvan and Robert Ehlinger. View Institutional Ownership Trends for Lannett Co.
Who sold Lannett Co stock? Who is selling Lannett Co stock?
Lannett Co's stock was sold by a variety of institutional investors in the last quarter, including Adams Diversified Equity Fund Inc.. Company insiders that have sold Lannett Co stock in the last year include David Farber, G Michael Landis and James M Maher. View Insider Buying and Selling for Lannett Co.
Who bought Lannett Co stock? Who is buying Lannett Co stock?
Lannett Co's stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., State of Alaska Department of Revenue and Municipal Employees Retirement System of Michigan. Company insiders that have bought Lannett Co stock in the last two years include Arthur P Bedrosian, David A Drabik, John Abt, Kevin Smith and Martin P Galvan. View Insider Buying and Selling for Lannett Co.
How do I buy Lannett Co stock?
Shares of Lannett Co can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lannett Co's stock price today?
One share of Lannett Co stock can currently be purchased for approximately $20.85.
MarketBeat Community Rating for Lannett Co (NYSE LCI)MarketBeat's community ratings are surveys of what our community members think about Lannett Co and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Lannett Co (NYSE:LCI) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $28.00 (34.29% upside) |
Analysts' Ratings History for Lannett Co (NYSE:LCI)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/17/2017 | Deutsche Bank AG | Reiterated Rating | Hold | $22.00 -> $23.00 | High |  |
| 6/8/2017 | Oppenheimer Holdings, Inc. | Reiterated Rating | Hold | | High | |
| 5/2/2017 | Roth Capital | Set Price Target | Buy | $27.00 | Medium | |
| 5/3/2017 | Robert W. Baird | Reiterated Rating | Outperform | $18.00 | Medium | |
| 5/1/2017 | BMO Capital Markets | Initiated Coverage | Market Perform | $29.00 | Medium | |
| 8/24/2016 | Raymond James Financial, Inc. | Boost Price Target | Outperform | $31.00 -> $43.00 | N/A | |
| 3/25/2016 | Susquehanna Bancshares Inc | Lower Price Target | | $37.00 -> $30.00 | N/A | |
| 3/25/2016 | Craig Hallum | Lower Price Target | Buy | $35.00 | N/A | |
| 3/24/2016 | Canaccord Genuity | Downgrade | Buy -> Sell | $28.00 -> $18.00 | N/A | |
(Data available from 7/27/2015 forward)
Earnings History for Lannett Co (NYSE:LCI)Earnings History by Quarter for Lannett Co (NYSE LCI)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/21/2017 | | $0.75 | | | | | N/A | |
| 5/2/2017 | Q3 2017 | $0.87 | $0.77 | $170.28 million | $165.72 million | View | Listen | |
| 2/1/2017 | Q217 | $0.84 | $0.92 | $169.04 million | $171.00 million | View | Listen | |
| 11/3/2016 | Q117 | $0.71 | $0.77 | $166.72 million | $161.60 million | View | N/A | |
| 8/23/2016 | Q416 | $0.59 | $0.73 | $161.55 million | $168.90 million | View | Listen | |
| 5/3/2016 | Q316 | $0.63 | $0.75 | $160.49 million | $163.70 million | View | N/A | |
| 2/3/2016 | Q216 | $0.94 | $0.95 | $141.62 million | $127.06 million | View | N/A | |
| 11/4/2015 | Q116 | $0.89 | $0.99 | $103.90 million | $106.40 million | View | N/A | |
| 8/25/2015 | Q415 | $0.86 | $0.91 | $97.21 million | $99.28 million | View | Listen | |
| 5/6/2015 | Q315 | $0.94 | $0.97 | $101.10 million | $99.40 million | View | N/A | |
| 2/4/2015 | Q215 | $1.06 | $1.21 | $102.95 million | $114.80 million | View | N/A | |
| 11/3/2014 | Q115 | $0.79 | $0.94 | $91.40 million | $93.40 million | View | N/A | |
| 8/27/2014 | Q414 | $0.63 | $0.64 | $79.50 million | $80.60 million | View | N/A | |
| 5/7/2014 | Q314 | $0.60 | $0.63 | $84.50 million | $80.00 million | View | N/A | |
| 2/6/2014 | Q214 | $0.39 | $0.46 | $62.21 million | $67.30 million | View | N/A | |
| 11/7/2013 | Q114 | $0.13 | $0.22 | $41.14 million | $45.82 million | View | N/A | |
| 9/10/2013 | Q4 2013 | $0.07 | $0.12 | $37.89 million | $40.20 million | View | N/A | |
| 5/8/2013 | Q3 2013 | $0.13 | $0.14 | $35.14 million | $39.00 million | View | N/A | |
| 2/7/2013 | Q2 2013 | $0.05 | $0.10 | $33.53 million | $36.60 million | View | N/A | |
| 11/8/2012 | Q113 | $0.05 | $0.07 | $33.76 million | $35.30 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Lannett Co (NYSE:LCI)2017 EPS Consensus Estimate: $3.28
2018 EPS Consensus Estimate: $2.89
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.65 | $0.73 | $0.69 |
| Q2 2017 | 3 | $0.80 | $0.91 | $0.86 |
| Q3 2017 | 3 | $0.82 | $0.93 | $0.89 |
| Q4 2017 | 3 | $0.72 | $0.93 | $0.84 |
| Q1 2018 | 1 | $0.68 | $0.68 | $0.68 |
| Q2 2018 | 1 | $0.76 | $0.76 | $0.76 |
| Q3 2018 | 1 | $0.72 | $0.72 | $0.72 |
| Q4 2018 | 1 | $0.73 | $0.73 | $0.73 |
(Data provided by Zacks Investment Research)
Dividend History for Lannett Co (NYSE:LCI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Lannett Co (NYSE:LCI)Insider Ownership Percentage: 15.04%
Institutional Ownership Percentage: 95.22%
Insider Trades by Quarter for Lannett Co (NYSE:LCI)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 2/6/2017 | Arthur P Bedrosian | CEO | Buy | 10,000 | $20.00 | $200,000.00 | |
| 12/2/2016 | David Farber | Major Shareholder | Sell | 3,800 | $25.00 | $95,000.00 | |
| 9/15/2016 | G. Michael Landis | Insider | Sell | 4,334 | $32.30 | $139,988.20 | |
| 9/1/2016 | James M Maher | Director | Sell | 1,478 | $33.91 | $50,118.98 | |
| 8/31/2016 | G. Michael Landis | Insider | Sell | 6,786 | $33.41 | $226,720.26 | |
| 6/23/2016 | Robert Ehlinger | VP | Sell | 37,141 | $25.06 | $930,753.46 | |
| 6/20/2016 | Robert Ehlinger | VP | Sell | 62,859 | $25.40 | $1,596,618.60 | |
| 3/1/2016 | Robert Ehlinger | VP | Sell | 69,247 | $25.41 | $1,759,566.27 | |
| 2/5/2016 | Arthur P Bedrosian | CEO | Buy | 4,500 | $24.91 | $112,095.00 | |
| 2/5/2016 | David A Drabik | Director | Buy | 1,277 | $24.74 | $31,592.98 | |
| 2/5/2016 | Kevin Smith | VP | Buy | 1,500 | $24.75 | $37,125.00 | |
| 2/5/2016 | Martin P Galvan | CFO | Buy | 3,000 | $24.65 | $73,950.00 | |
| 9/15/2015 | Arthur P Bedrosian | CEO | Sell | 5,000 | $55.64 | $278,200.00 | |
| 9/8/2015 | John Abt | VP | Buy | 1,000 | $54.77 | $54,770.00 | |
| 8/17/2015 | Arthur P Bedrosian | CEO | Sell | 5,000 | $52.81 | $264,050.00 | |
| 7/15/2015 | Arthur P Bedrosian | CEO | Sell | 5,000 | $61.92 | $309,600.00 | |
| 6/15/2015 | Arthur P Bedrosian | CEO | Sell | 5,000 | $56.31 | $281,550.00 | |
| 5/15/2015 | Arthur P Bedrosian | CEO | Sell | 5,000 | $53.27 | $266,350.00 | |
| 4/15/2015 | Arthur P Bedrosian | CEO | Sell | 5,000 | $69.43 | $347,150.00 | |
| 3/16/2015 | Arthur P Bedrosian | CEO | Sell | 5,000 | $65.23 | $326,150.00 | |
| 3/16/2015 | William Schreck | COO | Sell | 134,635 | $64.99 | $8,749,928.65 | |
| 3/6/2015 | William Schreck | COO | Sell | 50,000 | $63.35 | $3,167,500.00 | |
| 2/18/2015 | David A Drabik | Director | Sell | 12,500 | $61.55 | $769,375.00 | |
| 2/17/2015 | Arthur P Bedrosian | CEO | Sell | 5,000 | $59.89 | $299,450.00 | |
| 2/17/2015 | G. Michael Landis | Insider | Sell | 11,500 | $58.60 | $673,900.00 | |
| 2/13/2015 | Jeffrey Farber | Director | Sell | 35,000 | $58.18 | $2,036,300.00 | |
| 2/11/2015 | Kevin Smith | VP | Sell | 109,436 | $56.51 | $6,184,228.36 | |
| 2/9/2015 | David Farber | Major Shareholder | Sell | 2,500 | $55.00 | $137,500.00 | |
| 2/9/2015 | Kevin Smith | VP | Sell | 53,534 | $55.36 | $2,963,642.24 | |
| 2/6/2015 | G. Michael Landis | Insider | Sell | 12,049 | $52.93 | $637,753.57 | |
| 1/26/2015 | David Farber | Major Shareholder | Sell | 7,500 | $50.00 | $375,000.00 | |
| 1/15/2015 | Arthur P Bedrosian | CEO | Sell | 5,000 | $43.50 | $217,500.00 | |
| 12/15/2014 | Arthur P Bedrosian | CEO | Sell | 5,000 | $43.81 | $219,050.00 | |
| 12/10/2014 | Martin P Galvan | CFO | Buy | 1,000 | $42.40 | $42,400.00 | |
| 12/8/2014 | Ernest Sabo | VP | Sell | 6,000 | $48.03 | $288,180.00 | |
| 10/27/2014 | David Farber | Major Shareholder | Sell | 7,500 | $50.00 | $375,000.00 | |
| 9/16/2014 | Arthur P Bedrosian | CEO | Sell | 5,000 | $40.05 | $200,250.00 | |
| 8/18/2014 | David Farber | Major Shareholder | Sell | 5,000 | $41.30 | $206,500.00 | |
| 7/15/2014 | Arthur P Bedrosian | CEO | Sell | 5,000 | $47.19 | $235,950.00 | |
| 6/23/2014 | David Farber | Major Shareholder | Sell | 7,500 | $50.00 | $375,000.00 | |
| 6/16/2014 | Arthur P Bedrosian | CEO | Sell | 5,000 | $46.96 | $234,800.00 | |
| 6/16/2014 | David Farber | Major Shareholder | Sell | 10,000 | $43.53 | $435,300.00 | |
| 6/16/2014 | Paul Taveira | Director | Sell | 1,000 | $46.94 | $46,940.00 | |
| 3/17/2014 | William Schreck | COO | Sell | 16,600 | $43.85 | $727,910.00 | |
| 3/12/2014 | William Schreck | COO | Sell | 55,563 | $43.31 | $2,406,433.53 | |
| 2/20/2014 | Kevin Smith | VP | Sell | 64,665 | $45.11 | $2,917,038.15 | |
| 2/13/2014 | Kevin Smith | VP | Sell | 20,000 | $40.48 | $809,600.00 | |
| 12/13/2013 | Arthur Bedrosian | CEO | Buy | 5,000 | $27.85 | $139,250.00 | |
| 12/13/2013 | Martin Galvan | CFO | Buy | 3,000 | $26.90 | $80,700.00 | |
| 5/14/2013 | Kevin Smith | VP | Sell | 24,984 | $11.86 | $296,310.24 | |
| 5/13/2013 | Kevin Smith | VP | Sell | 41,929 | $11.80 | $494,762.20 | |
| 5/10/2013 | Ernest Sabo | VP | Sell | 15,000 | $11.29 | $169,350.00 | |
| 3/14/2013 | Paul Taveira | Director | Buy | 1,000 | $9.73 | $9,730.00 | |
| 2/13/2013 | Martin P Galvan | CFO | Buy | 4,000 | $6.88 | $27,520.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Lannett Co (NYSE:LCI)
Latest Headlines for Lannett Co (NYSE:LCI)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to Lannett Co., Inc. : July 24, 2017
finance.yahoo.com - July 25 at 2:29 AM |
 | Lannett Company, Inc. (LCI) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - July 24 at 9:04 PM |
| Deutsche Bank AG Increases Lannett Co Inc (LCI) Price Target to $23.00
www.americanbankingnews.com - July 17 at 7:15 PM |
 | Lannett Appoints Samuel H. Israel As General Counsel - PR Newswire - PR Newswire (press release)
www.prnewswire.com - July 17 at 12:54 PM |
| Lannett Appoints Samuel H. Israel As General Counsel
finance.yahoo.com - July 17 at 12:54 PM |
| Corporate News Blog - Lannett Co. Receives Approval for Cyproheptadine Hydrochloride Syrup
finance.yahoo.com - July 17 at 12:54 PM |
| Fox Rothschild partner becomes general counsel of local drug manufacturer
finance.yahoo.com - July 17 at 12:54 PM |
| FY2018 EPS Estimates for Lannett Co Inc (NYSE:LCI) Increased by Oppenheimer Holdings
www.americanbankingnews.com - July 17 at 10:30 AM |
| Lannett Receives Approval For Cyproheptadine Hydrochloride Syrup, 2 mg/5 mL - PR Newswire (press release)
www.prnewswire.com - July 16 at 12:34 PM |
 | FDA OKs Lannett's generic cyproheptadine hydrochloride syrup
seekingalpha.com - July 15 at 5:26 AM |
| Lannett Receives Approval For Cyproheptadine Hydrochloride Syrup, 2 mg/5 mL
finance.yahoo.com - July 15 at 5:26 AM |
| Lannett Co Inc to Post FY2017 Earnings of $3.18 Per Share, Oppenheimer Holdings Forecasts (LCI)
www.americanbankingnews.com - July 14 at 11:22 AM |
| ETFs with exposure to Lannett Co., Inc. : July 12, 2017
finance.yahoo.com - July 13 at 6:17 AM |
| Zacks: Analysts Anticipate Lannett Co Inc (LCI) Will Post Quarterly Sales of $162.91 Million
www.americanbankingnews.com - July 7 at 1:32 PM |
| Lannett Co Inc (NYSE:LCI) Expected to Post Earnings of $0.74 Per Share
www.americanbankingnews.com - July 5 at 2:08 PM |
| Lannett Co., Inc. breached its 50 day moving average in a Bullish Manner : LCI-US : July 4, 2017
finance.yahoo.com - July 4 at 6:04 PM |
| Corporate News Blog - Lannett Receives Approval for Additional Dosage Strengths of Hydrocodone Bitartrate and Acetaminophen Tablets USP
finance.yahoo.com - June 28 at 7:51 PM |
 | Lannett (LCI) Granted Approval For Additional Dosage Strengths Of ... - StreetInsider.com
www.streetinsider.com - June 27 at 11:28 PM |
| Lannett Co Inc (LCI) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - June 27 at 6:40 PM |
| Lannett: Bullish Possibilities Despite Massive Short Interest
seekingalpha.com - June 27 at 6:26 PM |
| Lannett Receives Approval For Additional Dosage Strengths Of Hydrocodone ...
www.prnewswire.com - June 26 at 8:10 PM |
| Lannett Receives Approval For Additional Dosage Strengths Of Hydrocodone Bitartrate And Acetaminophen Tablets USP
finance.yahoo.com - June 26 at 8:10 PM |
| Lannett Receives Approval For Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg And 10 mg/300 mg
finance.yahoo.com - June 22 at 12:35 PM |
| Lannett Names Patrick G. LePore To Board of Directors
finance.yahoo.com - June 20 at 7:13 PM |
| ETFs with exposure to Lannett Co., Inc. : June 19, 2017
finance.yahoo.com - June 19 at 5:18 PM |
| Lannett (LCI) Granted FDA Approval for Niacin Extended-Release Tablets USP, 500 Mg & 1000 Mg
www.streetinsider.com - June 19 at 11:57 AM |
| FDA approves Lannett's Niacin USP, 500 mg and 1000 mg
seekingalpha.com - June 19 at 11:56 AM |
| Lannett Receives Approval For Niacin Extended-Release Tablets USP, 500 Mg And ...
www.prnewswire.com - June 19 at 11:56 AM |
| Lannett Receives Approval For Niacin Extended-Release Tablets USP, 500 Mg And 1000 Mg
finance.yahoo.com - June 19 at 11:56 AM |
| Featured Company News - Lannett Announces Approval for Amantadine Hydrochloride Capsules USP, 100 mg; Set to Launch Before the Flu Season
finance.yahoo.com - June 19 at 11:56 AM |
| Lannett (LCI) Receives FDA Approval For Amantadine Hydrochloride Capsules USP, 100 mg
www.streetinsider.com - June 17 at 11:50 PM |
| Lannett Announces Approval For Amantadine Hydrochloride Capsules USP, 100 mg - PR Newswire (press release)
www.prnewswire.com - June 16 at 7:12 PM |
| Lannett Announces Approval For Amantadine Hydrochloride Capsules USP, 100 mg
finance.yahoo.com - June 16 at 7:12 PM |
| Lannett Co., Inc. :LCI-US: Earnings Analysis: Q3, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 7:12 PM |
| Lannett (LCI) Receives FDA Approval For Amantadine Hydrochloride Capsules USP, 100 mg - StreetInsider.com
www.streetinsider.com - June 16 at 7:16 AM |
| Comparing Lannett Co (LCI) & Neos Therapeutics (NEOS)
www.americanbankingnews.com - June 13 at 8:17 AM |
| Head-To-Head Analysis: AMAG Pharmaceuticals (AMAG) & Lannett Co (LCI)
www.americanbankingnews.com - June 12 at 10:52 AM |
| Lannett Company, Inc. (LCI) Rating Reiterated by Oppenheimer Holdings Inc.
www.americanbankingnews.com - June 11 at 9:02 AM |
| Lannett Company, Inc. (LCI) Expected to Announce Quarterly Sales of $162.91 Million
www.americanbankingnews.com - June 11 at 8:52 AM |
| Zacks: Analysts Expect Lannett Company, Inc. (LCI) Will Post Earnings of $0.74 Per Share
www.americanbankingnews.com - June 9 at 4:30 PM |
| Lannett Company, Inc. (LCI) Rating Lowered to Hold at ValuEngine
www.americanbankingnews.com - June 4 at 9:20 AM |
| Lannett Company, Inc. (LCI) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - June 2 at 10:50 AM |
| Lannett Company's Chief Executive Officer Receives High Rating - PR Newswire (press release)
www.prnewswire.com - May 26 at 7:04 PM |
| Lannett Company's Chief Executive Officer Receives High Rating
finance.yahoo.com - May 26 at 7:04 PM |
| Lannett (LCI) Reports FDA Approval for Levocetirizine Dihydrochloride Oral Solution, 2.5 mg/5 mL
www.streetinsider.com - May 17 at 6:14 PM |
| Brokerages Expect Lannett Company, Inc. (LCI) Will Post Quarterly Sales of $162.91 Million
www.americanbankingnews.com - May 17 at 12:00 PM |
| Lannett Announces Approval For Levocetirizine Dihydrochloride Oral Solution, 2.5 mg/5 mL (0.5 mg/mL) - PR Newswire (press release)
www.prnewswire.com - May 16 at 6:06 PM |
| Lannett Announces Approval For Levocetirizine Dihydrochloride Oral Solution, 2.5 mg/5 mL (0.5 mg/mL)
finance.yahoo.com - May 16 at 10:46 AM |
| Analysts Anticipate Lannett Company, Inc. (LCI) Will Announce Earnings of $0.74 Per Share
www.americanbankingnews.com - May 15 at 10:10 AM |
| Lannett Voluntarily Pays Down Remaining $25 Million Principal ... - PR Newswire (press release)
www.prnewswire.com - May 10 at 12:57 PM |
Lannett Co (LCI) Chart for Thursday, July, 27, 2017
